Rubicon OrganicsROMJF 50 Earnings Yield (Joel Greenblatt) % is -1.46% as of Mar. 2026. GuruFocus rates ROMJF with a GF Score™ of 50/100 and a GF Value™ of $0.39 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,016 Drug Manufacturers companies, Rubicon Organics ranks worse than 73.52% on this metric.
Rubicon Organics's Enterprise Value for the quarter that ended in Mar. 2026 was $31.58 Mil.
Rubicon Organics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.47 Mil. Rubicon Organics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was -1.46%.
The historical rank and industry rank for Rubicon Organics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ROMJF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -40.61 Med: -7.89 Max: 11.73
Current: -1.56
During the past 10 years, the highest Earnings Yield (Joel Greenblatt) of Rubicon Organics was 11.73%. The lowest was -40.61%. And the median was -7.89%.
ROMJF's Earnings Yield (Joel Greenblatt) % is ranked worse than 73.52% of 1016
companies
in the Drug Manufacturers industry
Industry Median: 3.24
vs ROMJF: -1.56
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Rubicon Organics's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Rubicon Organics Earnings Yield (Joel Greenblatt) % Related Terms
Rubicon Organics Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Rubicon Organics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROMJF vs ZTS, UTHR: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rubicon Organics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Organics Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Organics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Rubicon Organics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Rubicon Organicss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Rubicon Organics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -1.46% mean?
Rubicon Organics (ROMJF) has a Earnings Yield (Joel Greenblatt) % of -1.46% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Rubicon Organics and its competitors. According to the industry distribution chart, Rubicon Organics ranks #747 out of 1016 companies in the Drug Manufacturers industry, placing it in the top 73.5%.
Is Rubicon Organics' Earnings Yield (Joel Greenblatt) % too high?
Rubicon Organics' current Earnings Yield (Joel Greenblatt) % is -1.46%. Based on the distribution chart, Rubicon Organics ranks #747 out of 1016 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Rubicon Organics has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rubicon Organics' Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rubicon Organics ranks #747 out of 1016 companies for Earnings Yield (Joel Greenblatt) %. This places Rubicon Organics in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.24, based on 1,016 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Rubicon Organics and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Organics's current Earnings Yield (Joel Greenblatt) % is -1.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Organics stock overvalued right now?
Based on GuruFocus' analysis, Rubicon Organics (ROMJF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.39, compared to a current price of $0.31 — trading 21.6% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -1.46%. Rubicon Organics' overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Rubicon Organics (ROMJF), the current Earnings Yield (Joel Greenblatt) % is -1.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rubicon Organics (ROMJF) Overvalued in 2026?
Based on GuruFocus' analysis, Rubicon Organics stock appears to be undervalued.
The current stock price of $0.31 is trading 21.6% below its estimated GF Value™ of $0.39.
GuruFocus considers Rubicon Organics to be Modestly Undervalued.
Key valuation signals for ROMJF:
Earnings Yield (Joel Greenblatt) %: -1.46%
GF Value™: $0.39 vs. price of $0.31 (21.6% below fair value)
No single metric tells the full story. See the ROMJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rubicon Organics Inc is engaged in the production and sale of cannabis in Canada. The company produces and processes organic cannabis at its wholly owned, federally licensed 125,000 square foot facility in Delta, British Columbia which it sells under its wholly owned brands and certain wholesale channels. Its brands include Simply Bare, 1964 Supply Co, Wildflower, and Homestead Cannabis Supply. It operates in a single reportable segment, being the production and sale of cannabis in Canada.
50GF Score
Get the complete analysis for ROMJF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROMJF has been successfully added to your 
